Cargando…
Opening the OPK Assay Gatekeeper: Harnessing Multi-Modal Protection by Pneumococcal Vaccines
Pneumococcal vaccine development is driven by the achievement of high activity in a single gatekeeper assay: the bacterial opsonophagocytic killing (OPK) assay. New evidence challenges the dogma that anti-capsular antibodies have only a single function that predicts success. The emerging concept of...
Autores principales: | Riegler, Ashleigh N., Mann, Beth, Orihuela, Carlos J., Tuomanen, Elaine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963391/ https://www.ncbi.nlm.nih.gov/pubmed/31652741 http://dx.doi.org/10.3390/pathogens8040203 |
Ejemplares similares
-
Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines
por: Scott, Ninecia R., et al.
Publicado: (2021) -
Dynamic capsule restructuring by the main pneumococcal autolysin LytA in response to the epithelium
por: Kietzman, Colin C., et al.
Publicado: (2016) -
Pneumococcal neuraminidase activates TGF-β signalling
por: Gratz, Nina, et al.
Publicado: (2017) -
Tiny Gatekeepers: Microbial Control of Host Drug Transporters
por: Kyaw, Than S., et al.
Publicado: (2022) -
Harnessing the gatekeepers of glucocorticoids for chemoprevention of non‐melanoma skin cancer
por: Mancha‐Ramirez, Anna M., et al.
Publicado: (2018)